Bifunctional Polypeptides for Complement and Angiogenesis Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for complement-mediated disorders often lack specificity and efficacy in modulating the complement system, particularly in inhibiting excessive activation and angiogenesis.
Innovation Solution
Development of polypeptides that specifically bind to C3 and/or C3b, inhibiting the classical and alternative complement pathways, and simultaneously inhibit angiogenesis by binding to VEGF, thereby treating disorders associated with complement activation and excessive angiogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for complement-mediated disorders, then treatment is provided, but specificity and efficacy in modulating the complement system are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying amino acid sequences of polypeptides (specifically positions 8, 9, 10, 22, 23, 25, 27, 30, 32, 34, 42, 44, 46, and 48) to optimize binding affinity to C3 and C3b while maintaining complement inhibition activity. This sequence optimization resolves the contradiction by enhancing efficacy through precise parameter adjustment without increasing structural complexity
Solution Approach 2:
The patent creates bifunctional polypeptides that simultaneously inhibit complement activation and angiogenesis by targeting both C3 and VEGF. This multi-functionality approach resolves the contradiction by providing comprehensive treatment efficacy for disorders involving both complement-mediated damage and pathological angiogenesis, such as age-related macular degeneration
2Reliability
If polypeptides with improved binding affinity are developed, then efficacy is enhanced, but complexity of the polypeptide structure increases
Solution Approach 1:
The patent optimizes binding affinity by making targeted amino acid substitutions at specific positions (4-22 substitutions from the Sac7d family consensus sequence) rather than extensive structural modifications. This resolves the contradiction by achieving high binding affinity through precise parameter changes while maintaining relatively simple polypeptide structures
Solution Approach 2:
The patent creates fusion proteins that combine C3-binding polypeptides with VEGF-inhibiting domains. This composite structure resolves the contradiction by achieving enhanced overall efficacy through functional combination while each domain maintains its own optimized binding characteristics without requiring complex redesign
3Adaptability or versatility
If bifunctional proteins are used to inhibit both complement and angiogenesis, then versatility is improved, but manufacturing complexity increases
Solution Approach 1:
The patent merges C3-binding polypeptides and VEGF-inhibiting domains into single bifunctional fusion proteins. This combining approach resolves the contradiction by providing versatile therapeutic coverage for both complement-mediated damage and angiogenesis in a single molecule, simplifying manufacturing compared to producing and coordinating multiple separate agents
Solution Approach 2:
The bifunctional polypeptides provide universal therapy for disorders involving both complement activation and pathological angiogenesis, such as age-related macular degeneration. This multi-functionality resolves the contradiction by enabling a single agent to address multiple pathological mechanisms, enhancing versatility without requiring complex multi-agent regimens
Data Source
AI summary
Proteins comprising a C3 and/or C3b binding polypeptide and a VEGF inhibitor, and their use in treating complement-mediated disorders, are described.